Commentary: triple therapy for patients with chronic hepatitis C and advanced fibrosis? Authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 11-12, 2013-12 ,pp. : 1408-1408

John Wiley & Sons Inc

Access to resources Recommend Favorite

Telaprevir‐based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 9, 2013-11 ,pp. : 1076-1085

John Wiley & Sons Inc

Access to resources Recommend Favorite

Chronic hepatitis C in Swedish subjects receiving opiate substitution therapy—Factors associated with advanced fibrosis

By Jerkeman Anna   Westin Johan   Lagging Martin   Norkrans Gunnar   Lidman Christer   Frimand Jan   Simonsberg Christian   Kakko Johan   Widell Anders   Björkman Per  

Scandinavian Journal of Infectious Diseases, Vol. 46, Iss. 5, 2014-05 ,pp. : 340-347

Informa Healthcare

Access to resources Recommend Favorite

P169: The rate of hepatic decompensation of chronic Hepatitis C patients with advanced fibrosis after achieving sustained virological response

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 103-103

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk of infections during interferon‐based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 6, 2015-06 ,pp. : 1057-1064

John Wiley & Sons Inc

Access to resources Recommend Favorite